Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.54 |
| ▸ | RORC | P51449 | 6/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | IL17A | Q16552 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699984 | 0.88 | XDH (0.54) | XDHRORC | |
| SCHEMBL20476411 | 0.80 | XDH (0.46) | XDHRORCSCN9A | |
| SCHEMBL17708411 | 0.78 | XDH (0.57) | XDHIKBKETBK1IDH1 | |
| SCHEMBL20529251 | 0.77 | RORC (0.51) | RORCSCN9AIL17A | |
| SCHEMBL29660023 | 0.76 | RORC (0.51) | XDHRORCIL17A | |
| SCHEMBL1231565 | 0.76 | TRPV4 (0.54) | XDH | |
| SCHEMBL20870757 | 0.76 | RORC (0.45) | RORCSCN9AIL17A | |
| SCHEMBL29660038 | 0.76 | RORC (0.45) | RORCSCN9AIL17A | |
| SCHEMBL17708065 | 0.75 | XDH (0.54) | XDHIKBKETBK1IDH1 | |
| SCHEMBL18994992 | 0.75 | XDH (0.54) | XDHRORCIKBKETBK1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| CN-111094267-B | Sulfonyl-substituted bicyclic compounds as ROR gamma inhibitors | 正大天晴药业集团股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3689860-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| CN-111094267-A | Sulfonyl-substituted bicyclic compounds as ROR gamma inhibitors | 正大天晴药业集团股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | RORC, RORA, RORB | XDH 2362/4885RORC 1/4885SCN9A 1144/4885 |
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | RORC, RORA, RORB | XDH 2362/4885RORC 1/4885SCN9A 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.